Clinical Trial: An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923747) titled 'An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)' on Nov. 02.

Brief Summary: The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis and Systemic Lupus Erythematosus

Intervention: DRUG: DKB903

DKB903

Recruitmen...